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Abstract
Background: Intermittent preventive treatment in infants (IPTi) with sulphadoxine-pyrimethamine (SP) reduces the
incidence of malaria episodes in young children. The exact mechanism by which the protective effect is mediated needs
to be defined. This study aimed to investigate therapeutic, prophylactic, and possible exceeding effects of SP-based IPTi
in two clinical trials.
Methods: Protective efficacies from two IPTi trials performed in Kumasi, Ghana, and Lambaréné, Gabon, were assessed
for overlapping time series of 61 days. For six-months periods after each of three IPTi doses a multivariate Poisson
regression model with the respective cohort as co-variate was generated and effect modification of protective efficacy
with time strata was evaluated by log-likelihood tests.
Results: Protective efficacies were not significantly different between the two study cohorts. Study-cohort corrected
protective efficacy was highest for the first 61 days after each IPTi application and decreased continuously. For the first
61 days after IPTi-1, IPTi-2, and IPTi-3 the protective efficacy was 71%, 44%, and 43%, respectively. A reduction of the
malaria incidence rate was detectable for the first 60, 30 and 40 days after IPTi-1, IPTi-2 and IPTi-3 drug application,
respectively. After IPTi-3 a higher risk for malaria could be seen after day 60. This effect was mainly based on the
overwhelming influence of the Kumasi cohort.
Conclusion: The results suggest that SP-based IPTi mainly works through a therapeutic and prophylactic effect over 30
to 60 days after drug application and that a sustained effect beyond post-treatment prophylaxis might be very low.
Trial registration: Data analysis from clinical trials NCT ID # 00206739 (Kumasi Trial) and NCT ID # 00167843
(Lambaréné Trial), http://www.clinicaltrials.gov.
Published: 1 October 2008
Malaria Journal 2008, 7:198 doi:10.1186/1475-2875-7-198
Received: 5 August 2008
Accepted: 1 October 2008
This article is available from: http://www.malariajournal.com/content/7/1/198
© 2008 May et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Malaria Journal 2008, 7:198 http://www.malariajournal.com/content/7/1/198
Page 2 of 8
(page number not for citation purposes)
Background
There is an urgent need to improve malaria control strate-
gies for young African children who represent the popula-
tion with highest risk for malaria-related morbidity and
mortality [1]. In most parts of sub-Saharan Africa individ-
ual control measures are restricted to the reduction of
transmission by the use of insecticide-treated bed nets [2]
and the treatment of malaria attacks [3], often with an
ineffective drug due to parasite drug resistance [4]. Prom-
ising new approaches such as multi-stage vaccines [5] and
intermittent preventive treatment in infants (IPTi) [6] aim
to inhibit the multiplication of Plasmodium falciparum
after infection.
The concept of IPTi is to combine both therapeutic and
prophylactic effects of an anti-malaria drug administered
in intervals short enough to prevent the onset of disease
and long enough to enable the development of protective
immunity [7]. However, it is unclear which factors con-
tribute to the effects of IPTi and whether an exceeding
impact exists. It has been suggested that the optimal drug
application schedule depends on the half-life of the drug
used, the extent of parasitic resistances against the drug,
and the incidence of malaria in the area [8].
The application scheme initially evaluated in Tanzania
was pragmatically linked to the extended program of
immunization (EPI) of the WHO at months 2, 3 and 9
and based on a weight-adjusted single dose of sulphadox-
ine-pyrimethamine (SP) [9]. The protective efficacy of the
intervention to reduce malaria episodes was more than
50% in an area with a malaria incidence of 0.43 per per-
son years. Subsequent studies in different African coun-
tries demonstrated a protective efficacy ranging between
17% and 25% [10-14].
Impairment of immune responses after routine vaccina-
tions or clinical rebound effects known to occur after con-
tinuous chemoprophylaxis have not been reported
[9,12,15,16], but concern exists about a possible rebound
with higher incidence of malaria in two studies, particula-
rily with high parasite densities [13,14]. The present study
compared therapeutic, prophylactic, and exceeding effects
of SP-based IPTi in study cohorts from Ghana and Gabon.
Methods
This study was performed with study cohorts from two
African sites with differing malaria endemicities. Main
results of the clinical trials on protective efficacy and safety
have been published elsewhere [10,11].
Study areas
Kumasi cohort
The Afigya Sekyere district occupies an area of 714 km2 in
the forest belt of the Ashanti Region in Ghana close to the
regional capital Kumasi. Its population was counted in
the year 2000 census as 84,691 persons living in 16,173
households. Children under 12 months and under five
years of age accounted for 4.0% and 18.6% of the popula-
tion, respectively. The temperature varies from 20°C to
36°C with monthly rainfall varying from 2 mm in Febru-
ary to 400 mm in July. A major rainy season extends from
April to August and a minor one from October to Novem-
ber. The local economy is based on cash crops such as
cocoa, coffee and oil palm, although subsistence farming
and small scale trading are the main sources of income.
Malaria is holoendemic in this area with an entomologi-
cal inoculation rate (EIR) of about 400 infective bites per
individual per year. The predominant Plasmodium species
is P. falciparum (80–90%) and the principal malaria vec-
tors are mosquitoes either of the Anopheles gambiae com-
plex or A. funestus. During the time of the study the first-
line drug for treatment of uncomplicated malaria in
Ghana was changed from chloroquine to amodiaquine-
artesunate. Chloroquine resistance of P. falciparum has
spread nation-wide and the prevalence of molecular
markers for sulphadoxine and pyrimethamine resistance
is high in the study area [17]. The percentage of persons
with at least one insecticide-treated bed net (ITN) in the
Ashanti region is 1.6% [18].
Lambaréné cohort
Lambaréné is situated at the river Ogooué near the equa-
tor in the Moyen Ogooué province of Gabon, a typical
Central African rain forest area. The average temperature is
around 27°C and rainfall is high throughout the year with
a minimum in July and August. The entomological inocu-
lation rate is about 50 infectious bites per individual per
year, mainly from vectors of the A. gambiae complex.
Malaria transmission is perennial with limited seasonal
fluctuations. Only the short rainy season produces an
increase of parasite rates and densities.
The prevailing species is P. falciparum, responsible for
more than 90% of all infections, together with some P.
malariae and P. ovale infections. Parasite resistance against
SP is intermediate and that against chloroquine is high
and widespread [19,20]. Bed net use appeared to be high
in the population and was 80% in the study group, but
only a fraction of nets is impregnated and ITN coverage is
estimated to be only 5% [11].
Subjects and study design
Subjects
The data is based on randomized, placebo-controlled,
double-blinded clinical trials performed in Ghana and
Gabon. Detailed descriptions of the study design of both
cohorts have been published elsewhere [10,11]. Briefly,
monthly active follow-ups and passive visits between theMalaria Journal 2008, 7:198 http://www.malariajournal.com/content/7/1/198
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age of three and 21 months were considered for this anal-
ysis. During every visit, the children were examined clini-
cally by a staff physician and the medical history since the
last visit was assessed. At treatment visits, scheduled at 3,
9 and 15 months of age, blood was drawn and the study
drug was administered. A structured questionnaire and a
case report form were completed and documented on
each consultation. Bed net usage at the time of first study
drug administration was assessed by interview and, when-
ever feasible, inspection of the house was performed.
Children received either a single dose of 250 mg sul-
phadoxine and 12.5 mg pyrimethamine or placebo
(verum drug and placebo provided by Roche, Basel, Swit-
zerland) at the age of 3, 9 and 15 months (IPTi-1, IPTi-2,
IPTi-3, respectively). The substance was administrated
orally by spoon after crushing the substance and mixing
with water. Children were observed for 30 min, and a
repeated dose was given if vomiting occurred. Treatment
was stopped if the child vomited the second dose. Malaria
attacks were treated with an oral combination of artesu-
nate (4 mg/kg/day every 24 h over 3 days) and amodi-
aquine (10 mg/kg/day every 24 h over 3 days).
Inclusion criteria were (i) provision of parental written
informed consent or witnessed oral consent in the case of
illiteracy and (ii) permanent residency in the study area.
Exclusion criteria were (i) known or suspected allergy to
sulphonamides or pyrimethamine and/or signs and
symptoms thereof and (ii) history of severe hepatic or
renal dysfunction.
Kumasi cohort
Infants at the age of three months (n = 1070) were
enrolled in the health posts of nine villages during their
first contact for EPI vaccinations. Duration of the study
was from January 2003 to September 2005 (NCT ID #
NCT00206739, http://www.clinicaltrials.gov). In the
Kumasi cohort, a malaria episode was defined as the pres-
ence of any asexual P. falciparum parasitaemia (> 500 par-
asites/μl) and either a rectal temperature of at least 38.0°C
or a history of fever during the last 48 h reported by the
mother. Examination of blood films followed quality-
controlled standardized procedures [10]. The protocol
was approved by the Committee of Human Research,
Publications and Ethics, School of Medical Sciences,
Kwame Nkrumah University of Science and Technology,
Kumasi, Ghana.
Lambaréné cohort
Newborns (n = 1189) were recruited on the maternity
wards of the Albert Schweitzer Hospital (HAS) and the
General Hospital (HG) in Lambaréné. Duration of the
study was from 2002 to 2007 (NCT ID # 00167843, http:/
/www.clinicaltrials.gov). In the Lambaréné cohort,
malaria episodes were defined as events of fever (rectal
body temperature ≥ 38.5°C or fever reported to have
occurred during the preceding 48 h) together with asexual
P. falciparum parasitaemia. Parasitaemia was assessed
according to the Lambaréné method, as described else-
where [21]. The ethics committee of the International
Foundation of the HAS approved the study.
Statistical analysis
Data from questionnaires and forms were entered into a
database software and cross-checked within 5 days of each
visit at each site. All data of patients were treated confiden-
tially. Copies of all data, and the original source docu-
ments (report forms) were retained at each study site.
Analyses were performed with the STATA/MP software,
version 10.0 (College Station, TX, USA). Protective effica-
cies were calculated for an overlapping series of 61-days
periods (2-months periods) for intervals of six months
after each SP administration (IPTi-1, IPTi-2, and IPTi-3,
Figure 1). The first 61-day period started at the time of an
IPTi application, the second 61-day period started at day
10 after the IPTi application, and so on. The last period
ended at the time of the next IPTi application or six
months after the last IPTi application (IPTi-3).
A treatment with a single dose of an anti-malarial drug
without diagnosis will have a therapeutical effect only in
individuals infected with drug-sensitive parasites. Accord-
ingly, the potential therapeutic effect of IPTi was reflected
by the proportion of children infected at time of drug
administration not considering the drug sensitivity of the
isolate. The true therapeutic effect can be considered as the
potential therapeutic effect multiplied with the propor-
tion of sensitive strains.
A single dose of an anti-malarial drug can only have a pro-
phylactic effect if a reinfection with drug-sensitive para-
sites occurs during the time of effective drug levels.
Accordingly, the potential prophylactic effect of IPTi was
reflected by the proportion of children from the placebo
arm (without prophylaxis) infected during the five weeks
after drug administration without consideration of the
drug sensitivity of the isolate.
Protective efficacy against multiple malaria episodes was
determined by Poisson regression and defined as one
minus rate ratio. For the analysis of the therapeutic effect,
children were rated at risk for malaria during the complete
time of follow-up. For the analysis of the prophylactic
effect, children were not rated at risk for malaria for 21
days after preceding malaria episodes or after IPTi applica-
tion. A multivariate Poisson regression model corrected
for the study cohort (Kumasi or Lambaréné) was gener-
ated for the six months after each IPTi dose, and effectMalaria Journal 2008, 7:198 http://www.malariajournal.com/content/7/1/198
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modification of protective efficacy with time strata was
evaluated by log-likelihood tests. A significant protection
was defined as a 95% confidence interval not including a
0% protective efficacy according to an alpha value p <
0.05.
Results
Basic data
Basic data at time of IPTi-1 show that the study cohorts
and study arms were similar (Table 1).
Potential therapeutic effect of IPTi in dependence of application dose
In the Kumasi cohort, prevalences of parasitaemia at time
of IPTi-1, IPTi-2, and IPTi-3, were 14.8%, 18.2%, and
24.3%, respectively, expressing the proportion of IPTi
applications with a potential therapeutic effect on sensi-
tive strains. Only 1.7% (18/1069) of children in the
Kumasi cohort had malaria at the time of IPTi-1 applica-
tion (SP or placebo) (Table 2). Out of these 18 children
with malaria, eight were treated with SP and in 3 of these,
malaria was detected during the 61 days after the drug
application indicating either treatment failure or re-infec-
tion. At the time of the second and third IPTi application
8.2% and 9.1%, respectively, had malaria out of which
18.6% and 11.6% presented with treatment failure within
61 days. Only one malaria episode occurred during the
first 21 days after an IPTi application (after IPTi-3 in
Kumasi). In the Lambaréné cohort, prevalence of parasi-
taemia and malaria at the time of IPTi applications were
always lower than 1.5% (Table 2).
Potential prophylactic effect after IPTi application
In children not being treated (placebo arm), the propor-
tion of new malaria episodes during the 61 days after IPTi-
1 was 5.4% (24/449) in the Kumasi cohort and 0.4% (2/
484) in the Lambaréné cohort (Table 3). The incidence
rate during this time in the Kumasi and Lambaréné cohort
was 0.24 and 0.01 episodes per 61 days, respectively. In
Protective efficacies were calculated for overlapping series of 61-days periods for six months after each IPTi administration  (IPTi-1, first IPTi dose at month 3; IPTi-2, second IPTi dose at month 9; IPTi-3, third IPTi dose at month 15) Figure 1
Protective efficacies were calculated for overlapping series of 61-days periods for six months after each IPTi 
administration (IPTi-1, first IPTi dose at month 3; IPTi-2, second IPTi dose at month 9; IPTi-3, third IPTi dose 
at month 15). The first 61-day period started at the time of an IPTi application, the last period ended at the time of the next 
IPTi application or 6 months after the last IPTi application (IPTi-3).
01 2 1 8 6
IPTi-1 IPTi-2 IPTi-3
24 3 9 15 21
Table 1: Basic data at first dose of IPTi
Kumasi cohort Lambaréné cohort
SP Placebo SP Placebo
Participants, n 535 535 504 507
Age, mean days (sd) 90 (± 12) 89 (± 11) 96 (± 14) 97 (± 14)
Hb, mean g/dL (sd) 10.4 (± 1.4)a 10.3 (± 1.3)b 10.0 (± 1.2)c 9.8 (± 1.3)d
Anaemiae, % 2.1a 2.1b 0.9c 2.2d
Parasitaemia, geomean/μlf 681 779 790 1240
sd, standard deviation, SP, sulphadoxine-pyrimethamine
a n = 531
b n = 534
c n = 461
d n = 458
e Hb < 7.5 g/dL
f in those parasitaemicMalaria Journal 2008, 7:198 http://www.malariajournal.com/content/7/1/198
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this analysis, the first 21 days after a malaria episode or
malaria treatment were not counted as risk time for the
assessment of new malaria episodes.
Protective efficacy in dependence of the time after IPTi application
Protective efficacies calculated for 61-days periods were
not significantly different between the two study cohorts
(tested with log likelihood tests) and were analysed in a
pooled dataset with correction for the study cohort. Study-
cohort corrected protective efficacy was highest for the
first 61 days after each IPTi application and decreased con-
tinuously with time since drug application (first 61 days
after IPTi-1, IPTi-2, and IPTi-3 the protective efficacy was
71%, 44%, and 43%, respectively; Figure 2). After IPTi-1 a
significant protection was detectable until day 60 after
drug administration. The effect disappeared after day 30
and 40 after IPTi-2 and IPTi-3, respectively. Sixty days after
IPTi-3 an increased risk for malaria could be seen. This
effect was mainly based on the overwhelming influence of
the Kumasi cohort.
Discussion
The efficacy of IPTi to protect from malaria episodes was
between 17% and 62% in different African study areas
resulting in an overall protective efficacy of about 25–
30% [6,9-14]. The mechanism of how IPTi works is not
fully understood and it has not been demonstrated
whether protection is based exclusively on therapeutic
and prophylactic or on additional exceeding effects [6].
The data collected at the two study sites with very different
Table 2: Probability of parasitaemia and malaria at time of IPTi applicationa
IPTi-1 IPTi-2 IPTi-3
n % (CI) n % (CI) n % (CI)
Kumasi n = 1069 n = 1012 n = 944
Parasitaemia 158 14.8 (12.7–17.1) 184 18.2 (15.9–20.7) 229 24.3 (21.6–27.1)
Asymptomatic 140 13.1 (11.1–15.3) 101 10.0 (8.2–12.0) 143 15.1 (12.9–17.6)
Symptomatic 18 1.7 (1.0–2.6) 83 8.2 (6.6–10.1) 86 9.1 (7.4–11.1)
Lambaréné n = 1011 n = 836 n = 703
Parasitaemia 6 0.6 (0.2–1.3) 9 1.1 (0.5–2.0) 10 1.4 (0.7–2.6)
Asymptomatic 4 0.4 (0.1–1.0) 3 0.4 (0.07–1.0) 0 0.0 (0.0–0.5)b
Symptomatic 2 0.2 (0.02–0.7) 6 0.7 (0.2–1.6) 10 1.4 (0.7–2.6)
CI, 95% confidence interval.
Denominator is the number of samples with available parasite assessment at time of IPTi application. The difference between the proportion of 
infected individuals in Kumasi and Lambaréné was always significant with at least p < 0.0006.
a Application of SP or placebo at scheduled time of IPTi.
b One-sided, 97.5% confidence interval.
Table 3: Reinfection risk of untreated children during 61 days after scheduled time of IPTi application
Eventa IPTi-1 IPTi-2 IPTi-3
n % (CI) n % (CI) n % (CI)
Kumasi n = 449 n = 428 n = 368
Parasitaemia 90 20.0 (16.4–24.1) 107 25.0 (21.0–29.4) 111 30.2 (25.5–35.1)
Asymptomatic 66 14.6 (11.6–18.3) 62 14.5 (11.3–18.2) 61 16.6 (12.9–20.8)
Symptomatic 24 5.4 (3.5–7.8) 45 10.5 (7.8–13.8) 50 13.6 (10.3–17.5)
Lambaréné n = 484 n = 412 n = 317
Parasitaemia 3 0.6 (0.1–1.8) 12 2.9 (1.5–5.0) 3 1.0 (0.2–2.7)
Asymptomatic 1 0.2 (0.0–1.1) 1 0.2 (0.0–1.3)b 0 0.0 (0.0–1.2)b
Symptomatic 2 0.4 (0.1–1.5) 11 2.7 (1.3–4.7) 3 1.0 (0.2–2.7)
CI, 95% confidence interval.
Denominator is the number of children from the placebo group without parasitaemia at scheduled time of IPTi application and with at least one 
available parasite assessment during the 61 days after IPTi application. The difference between the proportion of infected individuals in Kumasi and 
Lambaréné was always significant with at least p < 0.0001.
a Nominators are number of events during 61 days after scheduled time of IPTi application.
b One-sided, 97.5% confidence interval.Malaria Journal 2008, 7:198 http://www.malariajournal.com/content/7/1/198
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malaria incidences presented here shows a similar picture
in terms of the protective effects. One limitation of the
analysis is the very low number of malaria episodes in
Lambaréné causing a reduced statistical power in this
cohort.
First, the potential therapeutical efficacy, namely the
probability of malaria at the time of IPTi application, is
expected to be directly dependent on the malaria inci-
dence in the area. Accordingly, it was about ten times
higher in the Kumasi than in the Lambaréné cohort. The
risk of malaria at time of SP application increased with age
in both sites. From the data presented here one can derive
that in highly endemic areas with relatively low frequen-
cies of parasite resistance, the therapeutic efficacy may
range from 1% to 25%.
Second, the potential prophylactic effect can be regarded
as the probability for malaria during the time in which
efficient blood levels are present. This probability is also
directly dependent on the malaria incidence rate. Accord-
ingly, it was significantly higher in Kumasi. In both study
sites and in contrast to the therapeutic efficacy the theoret-
ical prophylactic effect increased only slightly with age.
Third, and most importantly, the results presented here
indicate a significant „post treatment prophylaxis" (PTP)
against malaria episodes of IPTi, which was highest after
IPTi-1 and lower after IPTi-2 and IPTi-3. Possible explana-
tions for the decrease of the protective efficacy are a
decrease of dosage per body weight with age, changes in
the preexisting drug resistance, and the development of
semi-immunity which may equalize the drug effects in
both study arms [10].
The PTP decreased rapidly during the first weeks after IPTi
administration and then disappeared. Sixty days after
IPTi-3, the risk for malaria was increased in the Kumasi
cohort and might indicate a rebound effect. Such a
malaria rebound was not detected in the analyses per-
formed according to the pre-defined analysis protocols of
the clinical trials [8,11].
After IPTi-1, the dose with the highest protective efficacy,
a prolonged protective effect was detectable 35 days after
the complete elimination of the drugs, namely after five
half-lives of sulfadoxine. Due to the synergy of the two
components the effect of one treatment dose was esti-
mated to last as long as 60 days against sensitive parasite
strains [22,23]. In principle, the duration of the PTP might
be compromised by the drug dose, pharmacokinetics of
the drug used, and the resistance level of the parasites [22-
24]. In one study from Northern Ghana the protective
effect against malaria was 77% – 84% during the first
month after each dose of IPTi and -11% – 43% during the
second month, demonstrating a sharp decrease of the
effect during the first weeks after drug application [13].
There was no evidence for a sustained protective effect of
IPTi in the study cohorts analysed here. In the clinical trial
from Tanzania such exceeding impact was inconsistently
observed, depending on the analysis performed [9,25].
Only when children were included irrespective of malaria
episodes in the first 10 months of life such an effect could
be detected. Schellenberg et al. postulated that IPTi
decreases the risk of a first malaria episode, which itself is
a major risk factor for subsequent episodes [25]. An alter-
native explanation hinges on the assumption that P. falci-
parum and SP-based IPTi interact mainly in children with
Protective efficacies for intervals of 61 days for six months  after each SP administration (A, IPTi-1; B, IPTi-2; C, IPTi-3) Figure 2
Protective efficacies for intervals of 61 days for six 
months after each SP administration (A, IPTi-1; B, 
IPTi-2; C, IPTi-3). Solid lines, protective efficacy; vertical 
bars, 95% confidence intervals. The first 61-day interval 
started at the time of an IPTi application and the last interval 
ended at the time of the next IPTi application or 6 months 
after the last IPTi application (IPTi-3). Protective efficacy 
against multiple malaria episodes determined by Poisson 
regression and defined as one minus rate ratio. Children 
were not rated at risk for malaria for 21 days after preceding 
malaria episodes or after antimalarial treatment.
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subtherapeutic drug levels when acquiring new infections.
The authors hypothesized that the combined antiplasmo-
dial effects of SP, fetal haemoglobin, and maternal immu-
nity may prevent the development of new blood-stage
infections into clinical attacks. Corresponding to the
experimental observations of P. yoelii in mice, parasites
could have further been attenuated in vivo, resulting in an
enhanced opportunity to generate protective immune
responses [26].
Intervention effects might be underestimated in both
study cohorts because mild malaria episodes were treated
early, which inherently comprises the risk of equalization
of the study arms. This is of particular importance because
amodiaquine, a long half-life drug which might exert sim-
ilar effects as the study drug itself, was used in both
cohorts for the treatment of uncomplicated malaria epi-
sodes [27,28]. Indeed, immune responses after single-
dose SP applications in the Kumasi cohort indicated an
underestimation of the protective efficacy of IPTi [29].
Conclusion
The results suggest that the effect of SP-based IPTi is
mainly therapeutic and prophylactic. It should be taken
into account for the optimization of IPTi application
schedules that sustained effects beyond prophylaxis can-
not be expected in all settings and it remains unclear why
such effects were found in certain studies but not in oth-
ers. The optimal interval between two IPT applications in
infants might be mainly determined by the probability of
re-infections after the end of the synergistic drug effects,
which is dependent on the prevalence of parasite drug
resistance and the incidence of P. falciparum infections in
a specific area [7,24]. The observation that the IPTi effect
is mainly therapeutic and prophylactic might limit the
selection of drugs eligible for IPTi to those that are long-
acting. Though there are alternative candidate drugs that
may be feasible [30], the long pharmacological half-lives
of sulfadoxine and pyrimethamine render the combina-
tion suitable for IPTi [31]. Together with the unique prop-
erty of being a one-dose anti-malaria drug, having a
convenient safety profile, and being an inexpensive agent
seems to favour SP for IPTi at least for the time being, pro-
vided that it is not used as the first line drug for treating
malaria in the same area [30].
Footnote
Recently, a secondary analysis of data from a cluster-rand-
omized trial of SP-based IPTi in an area of intense sea-
sonal transmission also demonstrated that protection
against malaria lasts between 4 to 6 weeks, whereas the
level of protection was higher during the first weeks [32].
The methodology of this analysis was very similar to that
of the present work with the difference that the analysis
period was not for the same time periods (61 days in the
present analysis) but ended at time of the next IPTi appli-
cation.
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